Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

SIMPLE SUMMARY: Knowledge on the real-world outcomes of patients with advanced melanoma and the value of different endpoints for evaluating survival benefits is limited. We investigated the outcomes and different surrogate endpoints for overall survival (OS) in 664 pembrolizumab-treated patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohr, Peter, Scherrer, Emilie, Assaf, Chalid, Bender, Marc, Berking, Carola, Chandwani, Sheenu, Eigentler, Thomas, Grimmelmann, Imke, Gutzmer, Ralf, Haferkamp, Sebastian, Hassel, Jessica C., Hauschild, Axel, Herbst, Rudolf, Jiang, Ruixuan, Kähler, Katharina C., Krepler, Clemens, Kreuter, Alexander, Leiter, Ulrike, Loquai, Carmen, Meier, Friedegund, Pföhler, Claudia, Rudolph, Anja, Schadendorf, Dirk, Schiavone, Maximo, Schley, Gaston, Terheyden, Patrick, Ugurel, Selma, Ulrich, Jens, Utikal, Jochen, Weishaupt, Carsten, Welzel, Julia, Weichenthal, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997941/
https://www.ncbi.nlm.nih.gov/pubmed/35406577
http://dx.doi.org/10.3390/cancers14071804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997941/
https://www.ncbi.nlm.nih.gov/pubmed/35406577
http://dx.doi.org/10.3390/cancers14071804

Ejemplares similares